Pharmaceuticals, Biotechnology and Life Sciences
argenx, a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, has started dosing of the first patient in a Phase II proof-of-concept study of ARGX-113 in patients with primary immune thrombocytopenia (ITP).
A representative in Bosnia and Herzegovina’s Federation Parliament, Dennis Gratz, from central left winged civil liberal party “Nasa Stranka” has innitiated legalisation of cannabis as a cure.
Horizon Pharma, a biopharmaceutical company focused identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, has issued a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. patent application number 15/180,173…
Shire’s partner in Japan, Shionogi & Co has received the approval of the Japanese Ministry of Health, Labor and Welfare to manufacture and market Intuniv, a new, once-daily non-stimulant indicated for the treatment of attention deficit hyperactivity disorder (ADHD), a common psychiatric disorder in children and adolescents.
Mylan has acquired the global rights to the Cold-Eeze brand cold remedy line from ProPhase Labs, Inc.
GlaxoSmithKline’s new CEO Emma Walmsley, who takes over on April 1, has won a short-term reprieve from the threat of generic Advair with a delay in U.S. approval for Mylan’s copy of the blockbuster lung inhaler.
Matinas BioPharma has appointed a life sciences executive to its Board of Directors.
Probiodrug AG, a Germany based biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer`s disease (AD), has announced its financial results for the twelve-month period ending 31 December 2016.
Oncodesign, a biotechnology company serving the pharmaceutical industry in the discovery of new therapeutic molecules to fight cancer and other serious illnesses with no known effective treatment, has reported its full-year 2016 results.
Amryt, the pharmaceutical company focused on treatments for rare and orphan diseases, has reported its final results for the year ended 31 December 2016.